OncLive - Clinical Oncology News, Cancer Expert Insights
OncLive - Clinical Oncology News, Cancer Expert Insights
Spotlight
OncClub: Join the Chat on Trending Trials in CancerIn-person and virtual events just for HCPsLive Broadcast to Explore a Second Line Treatment Option for HER2+ Metastatic Breast Cancer Register to join us LIVE in Chicago for Giants of Cancer Care®Subscribe to our eNewsletter for breaking news and curated content
Specialty
View MoreBreast CancerCAR T-cell TherapyChronic Lymphocytic LeukemiaGastrointestinal CancerGenitourinary CancersGynecologic OncologyImmuno-OncologyLung CancerMelanoma & Skin CancerMultiple MyelomaUrothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
Rare Cancer Series
Media
Insights
Medical World News
News Network
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Thoracic Night Live
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Publications
Oncology Live
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Partners
Subscribe
eNewsletter
Print Subscription
  • Advertise
  • About OncLive
  • Editorial Board
  • CancerNetwork.com
  • CGTlive.com
  • CureToday.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information

© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Spotlight
  • OncClub: Join the Chat on Trending Trials in Cancer
  • In-person and virtual events just for HCPs
  • Live Broadcast to Explore a Second Line Treatment Option for HER2+ Metastatic Breast Cancer
  • Register to join us LIVE in Chicago for Giants of Cancer Care®
  • Subscribe to our eNewsletter for breaking news and curated content
SpecialtySee All >
  • Breast Cancer
  • CAR T-cell Therapy
  • Chronic Lymphocytic Leukemia
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Oncology
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Multiple Myeloma
  • Urothelial Cancer
OncLive SOSS
  • Advertise
  • About OncLive
  • Editorial Board
  • CancerNetwork.com
  • CGTlive.com
  • CureToday.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Thomas Powles, MD

  1. home

Articles

Dr. Powles on the Impact of Immunotherapy in Kidney Cancer

November 19th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

Dr. Powles on Bevacizumab Plus Atezolizumab in Kidney Cancer

July 19th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the combination of bevacizumab (Avastin) and atezolizumab (Tecentriq) versus single-agent atezolizumab versus sunitinib (Sutent), which was studied in the randomized, phase II IMmotion150 trial for patients with metastatic renal cell carcinoma (RCC).

Dr. Powles Discusses the Future of Durvalumab in Bladder Cancer

March 8th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the future of durvalumab in the treatment of bladder cancer.

Dr. Powles on Durvalumab in Urothelial Cancer

February 20th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.